An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants

Parsaclisib, a selective, potent phosphatidylinositol 3‐kinase delta inhibitor being developed for the treatment of cancer and autoimmune diseases, is primarily metabolized by cytochrome P450 (CYP) 3A4. This study assessed the pharmacokinetics (PK) and safety of parsaclisib alone or combined with it...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia, Rockich, Kevin, Yuska, Brad, Zhou, Gongfu, Epstein, Noam, Punwani, Naresh, Chen, Xuejun, Yeleswaram, Swamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586811/
https://www.ncbi.nlm.nih.gov/pubmed/32515832
http://dx.doi.org/10.1002/jcph.1653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586811/
https://www.ncbi.nlm.nih.gov/pubmed/32515832
http://dx.doi.org/10.1002/jcph.1653

Ejemplares similares